AMLX — AMYLYX PHARMACEUTICALS INC

Ownership history in ORBIMED ADVISORS LLC  ·  5 quarters on record

This page tracks every 13F SEC filing in which ORBIMED ADVISORS LLC reported a position in AMYLYX PHARMACEUTICALS INC (AMLX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.47% (2023 Q1)
Avg. % of fund
0.16%
First filed
2023 Q1
Last filed
2025 Q3
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 750,600 +437,400 +139.7% 0.24% $10.2M $13.59
2025 Q2 REDUCED 313,200 -34,800 -10.0% 0.05% $2.0M $6.41
2025 Q1 UNCHANGED 348,000 — 0% 0.03% $1.2M $3.54
2024 Q4 REDUCED 348,000 -465,500 -57.2% 0.03% $1.3M $3.78
2023 Q1 INITIATED 813,500 — — 0.47% $23.9M $29.34
% of Fund (quarterly)    AMLX price (monthly, adj. close)

Other funds also holding AMLX

As of 2025 Q4 — sorted by position size

Saturn V Capital Management LP 3Y 9.97% GREAT POINT PARTNERS LLC 3Y 7Y 6.85% Almitas Capital LLC 3Y 7Y 5.65% Commodore Capital LP 3Y 4.54% First Light Asset Management, LLC 3Y 7Y 3.1% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 2.73% TCG Crossover Management, LLC 3Y 2.5% Aldebaran Capital, LLC 3Y 2.15% PERCEPTIVE ADVISORS LLC 3Y 7Y 1.78% STEMPOINT CAPITAL LP 1.17%
← Back to ORBIMED ADVISORS LLC Holdings